Download PDF
Thromb Haemost 2005; 94(01): 1-3
DOI: 10.1160/TH05-05-0317
Editorial Focus
Schattauer GmbH

Early anti-thrombotic and anti-inflammatory actions of statins and fibrates – time for adjuvant therapy in acute coronary syndromes?

Jan Kristian Damås
1   Research Institute for Internal Medicine
2   Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet, University of Oslo, Oslo, Norway
,
Luca Puccetti
3   Department of Clinical Medicine and Immunological Sciences, Internal Medicine Division, Center for Atherosclerosis Research, Policlinico Le Scotte, University of Siena, Siena, Italy
,
Pål Aukrust
1   Research Institute for Internal Medicine
2   Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet, University of Oslo, Oslo, Norway
› Author Affiliations
Further Information

Publication History

Received 09 May 2005

Accepted 10 May 2005

Publication Date:
05 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
    CrossrefPubMedGoogle Scholar
  • 2 Libby P. Current consepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
    CrossrefPubMedGoogle Scholar
  • 3 Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-7.
    CrossrefPubMedGoogle Scholar
  • 4 Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation 2002; 105: 2937-8.
    CrossrefPubMedGoogle Scholar
  • 5 Kwak B, Mulhaupt F, Myit S. et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
    CrossrefPubMedGoogle Scholar
  • 6 Weitz-Schmidt G, Welzenbach K, Brinkmann V. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
    CrossrefPubMedGoogle Scholar
  • 7 Lazar MA. Progress in cardiovascular biology: PPAR for the course. Nat Med 2001; 7: 23-4.
    CrossrefPubMedGoogle Scholar
  • 8 Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21: 1891-5.
    CrossrefPubMedGoogle Scholar
  • 9 Marx N, Kehrle B, Kohlhammer K. et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-10.
    CrossrefPubMedGoogle Scholar
  • 10 Despres JP, Lemieux I, Pascot A. et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2003; 23: 702-3.
    CrossrefPubMedGoogle Scholar
  • 11 Undas A, Celinska-Lowenhoff M, Domagala TB. et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005; 93: 193-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Buffon A, Biasucci LM, Liuzzo G. et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
    CrossrefPubMedGoogle Scholar
  • 13 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-62.
    CrossrefPubMedGoogle Scholar
  • 14 Wibaut-Berlaimont V, Randi AM, Mandryko V. et al. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 2005; 3: 677-85.
    CrossrefPubMedGoogle Scholar
  • 15 Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascu lar biology. Curr Opin Lipidol 2004; 15: 637-43.
    CrossrefPubMedGoogle Scholar
  • 16 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
    CrossrefPubMedGoogle Scholar
  • 17 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
    CrossrefPubMedGoogle Scholar
  • 18 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Furman MI, Krueger LA, Linden MD. et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-25.
    CrossrefPubMedGoogle Scholar
  • 20 Aukrust P, Muller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-20.
    CrossrefPubMedGoogle Scholar
  • 21 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32: 901-8.
    CrossrefPubMedGoogle Scholar
  • 22 Puccetti L, Sawamura T, Pasqui AL. et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolemic patients. Eur J Clin Invest 2005; 35: 47-51.
    CrossrefPubMedGoogle Scholar